rapid upregulation of MHC class II expression after activation of DCs (these should have been cDCs, as pDCs were not defined at that time) 11,12 . These two papers did not agree on the exact mechanism. One group suggested that MHC class II turnover is inhibited in activated DCs 12 , whereas the other group suggested that MHC class II upregulation is mainly due to selective secretion 11 . Young and colleges now provide molecular support for the first model 12 by implementing selective MARCH1 expression 1 .
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This raises a new question; how is the regulator regulated, or what controls MARCH1 expression? MARCH1 is more or less selectively expressed in the immune system, especially on B cells and DCs 2, 3 . How MARCH1 is selectively downregulated in cDCs after activation by CpG is unclear. It should involve notable differences between pDCs and cDCs and could act at different levels, including transcriptional control and posttranscriptional control, such as by stabilizing or degrading MARCH1 itself.
Thus, pDCs and cDCs act differently in handling antigens encountered at different times after activation. This may have consequences for the use of DCs for vaccination purposes. When only peptide-MHC class II complexes are considered, cDCs should be superior for presenting peptides over long periods of time. However, when the net response of the respective DC types is considered, incorporating different costimulatory molecules, migration activity, cytokine-secretion patterns and many other parameters, successful application in a vaccine is more difficult to predict. The use of different DC types in vaccines must be determined on a vaccine-to-vaccine basis, as they may be optimal in defined conditions. volume 9 number 11 november 2008 nature immunology IFn-γ and self-absorbed Cd4 + T cells: a regulatory double negative
David Hildeman 1 & Edith Janssen 2
Interferon-γ exerts many effects on the immune system. A new report shows that it induces both autophagy and Irgm1, a GTPase that protects activated CD4 + T cells from executing autophagy. utophagy, an internal cellular degradation process activated in response to nutrient or growth-factor starvation, begins with the formation of an 'autophagosome', an intracellular membrane that engulfs portions of cytoplasm. After fusion with late endosomes or lysosomes, the contents of the fused autophagolysosome are degraded and recycled for the anabolic needs of the cell. Autophagy can have prosurvival effects as a short-term nutrient recycler, but left unchecked, it can have pro-death effects as well. Studies have emphasized the importance of autophagy in the turnover of damaged or inefficient organelles 1 , the control of pathogens 2, 3 and lymphocyte homeostasis 4 . Although much progress has been made in identifying the core machinery of autophagy, factors regulating the activation or suppression of autophagy remain unclear, particularly in the immune system.
In this issue of Nature Immunology, Feng et al. show that Irgm1 (also called LRG47) is an interferon-inducible GTPase that seems to suppress interferon-γ (IFN-γ)-induced autophagy in CD4 + T cells 5 . Building on published observations that Irgm1-deficient (Irgm1 -/-) mice develop severe CD4 + T cell lymphopenia during mycobaterial infection 6 , they now provide evidence that suggests this infection-induced CD4 + T cell attrition is due to autophagy and that superimposed IFN-γ deficiency negates such attrition. Hence, IFN-γ drives both a counter-regulatory mechanism (which would limit T helper type 1 (T H 1) responses) and an inhibitor of this negative regulatory mechanism-a regulatory 'double negative' (Fig. 1) .
Optimal population expansion of CD4 + T cells and, in particular, T H 1 cells is critical for many aspects of immune responses. These include the promotion of antibody responses, priming of CD8 + T cells and induction of CD8 + T cell memory, activation of phagocytic cells and limiting of T H 2 and interleukin 17-producing T helper (T H -17) responses. However, the clonal burst size of CD4 + T cell responses can vary by an order of magnitude depending on the immunization protocol. Although various mechanisms can contribute to optimal CD4 + T cell population expansion, the survival of proliferating CD4 + T cells is probably critical.
In their latest paper, Feng et al. focus on the mechanisms underlying the infectioninduced CD4 + T cell loss that occurs in Irgm1 -/-mice 5 . First, they find in standard proliferation assays with T cell receptor (TCR)-transgenic CD4 + T H 0 cells that incorporation of 3 H is impaired in Irgm1 -/-T cells relative to that in wild-type cells after peptide or TCR stimulation. This apparent failure to proliferate is probably not due to defects in T cell activation, as they show that CD25 expression, incorporation of the thymidine analog 5-bromodeoxyuridine, activation of the kinase Erk, degradation of the inhibitor IκBα and phosphorylation of the kinase Akt are all normal after TCR stimulation of Irgm1 -/-CD4 + T cells. Instead, by counting cell bodies, they find that most Irgm1 -/-CD4 + T cells die roughly 2-3 days after stimulation. IFN-γ is the main culprit that limits cell survival because blocking antibodies to IFN-γ prevent the death of activated Irgm1 -/-CD4 + T cells. This impaired survival is also present after restimulation of Irgm1 -/-T H 1 (but not T H 2) cells in vitro. Further, superimposed loss of IFN-γ expression restores 'proliferation' to Irgm1 -/-Ifng -/-CD4 + T cells in vitro and prevents attrition of CD4 + T cells after mycobacterial infection of Irgm1 -/-Ifng -/-mice in vivo. Finally, the addition of IFN-γ to cell cultures enhances the death of Irgm1 -/-Ifng -/-T cells but not Ifng -/-T cells because IFN-γ upregulates cell death-protective Irgm1 in Ifng -/-T cells. These data collectively suggest that IFN-γ drives the death of activated CD4 + T cells but also induces Irgm1, which protects against such cell death.
Although a published report has identified a function for IFN-γ in controlling activationinduced cell death of CD4 + T cells through modulation of signaling by the death receptor Fas 7 , the studies here suggest that IFN-γ can control CD4 + T cell death in ways that do not seem to involve Fas or its ligand. Furthermore, Feng et al. show that caspase inhibition does not prevent IFN-γ-induced death of Irgm1 -/-CD4 + T cells 5 , again challenging the idea of involvement of death receptors in this cell death. Finally, they demonstrate that expression of several members of the family of the antiapoptosis protein Bcl-2 is not affected by either IFN-γ or the absence of Irgm1, which suggests a lack of involvement of the mitochondrial cell death pathway. However, this does not completely rule out the possibility of involvement of either death receptor or mitochondrial pathways; more definitive assessment of these pathways with knockout and/or transgenic mice is needed before such a conclusion can be drawn.
Because IFN-γ can promote autophagy 2 , the authors next investigate the function of autophagy in the death of activated Irgm1 -/-CD4 + T cells by assessing several criteria that are consistent with autophagy. First, they find that treatment of Irgm1 -/-Ifng -/-CD4 + T cells with IFN-γ results in more autophagic vacuole-containing cells, as assessed by electron microscopy. Second, they use an overexpression system to assess aggregation of LC3 (also called ATG8), which is a distinguishing feature of autophagy. LC3 is conjugated to phosphatidylethanolamine and becomes incorporated and aggregated into the growing autophagosomal membrane 8 . They find that IFN-γ promotes LC3 aggregation in Irgm1 -/-Ifng -/-CD4 + T cells-not a trivial experiment, given the sparse cytoplasm of activated CD4 + T cells. Third, using small interfering RNA, they show that the death of activated Irgm1 -/-Ifng -/-but not Ifng -/-CD4 + T cells is mostly prevented by knockdown of beclin-1, a molecule critical for autophagy initiation. These data collectively suggest that IFN-γ is able to induce autophagic death in CD4 + T cells but only when Irgm1 is missing.
Notably, these data are in direct contrast to the purported function of Irgm1 in other cells. For example, in mouse macrophages, Irgm1 seems to be critical for IFN-γ-induced autophagy, which is itself a process critical for the intracellular elimination of mycobacteria 2, 9 . One possible explanation for this conundrum might be that Irgm1 has cell context-dependent effects on autophagy induction. In this scenario, differential expression of genes encoding modifiers may control the cell type-specific autophagic function of Irgm1. Genetic screens comparing activated macrophages versus activated CD4 + T cells may be a first step in identifying differentially expressed gene products that control autophagic processes operative in the two disparate cell types. The identification of such target genes might not only aid the understanding of autophagy but also provide therapeutic targets for a new class of antimicrobial agents to induce autophagy selectively in macrophages.
The work of Feng et al. 5 is also in contrast to other studies examining the function of autophagy in T cells. The autophagic protein ATG5 has been shown to be essential for normal lymphocyte homeostasis 4 , consistent with a prosurvival function for autophagy in T cells. One explanation might be that because of the low metabolic demands of resting lymphocytes, autophagy may provide supplementary nutrients to intermittently sustain the cells when environmental nutrients become limiting. However, in activated lymphocytes, metabolic demands are high and may supersede the ability of autophagy to safely supply them. Instead, activated CD4 + T cells increase glycolysis to meet energy demands 10, 11 rophages to enhance antimicrobial activity. In the end, the answer may be in the 'genes that fit' CD4 + T cells particularly well and prevent them from gorging on themselves while allowing them to become 'LRG'.
